Ann: Successful BARD1 Kit Evaluation, page-30

This is wild to me that the price has stagnated. We've basically derisked and having a working blood test for ovarian cancer as well as other cancers in the pipeline.. We are this close to commercialisation. I'd imagine if nothing else with our IP we'd make a fantastic take over target. It's a matter of time before BD1 stock price is re-rated to multiple x our current market cap.. My guess is that by early next year these prices will be a memory. We're so far ahead of other biotechs in that we actually have a working product, now it's just a waiting game until the money starts flowing in. Well done BD1 team

DYOR and have fun